Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ACCL16N1CD||COG||Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)||Pediatric CIRB||Available to Open|
|10301||ETCTN||A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)||Adult CIRB - Early Phase Emphasis||Available to Open|
|AOST06B1||COG||A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens||Pediatric CIRB||Available to Open|
|A171601||Alliance||A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer||Cancer Prevention and Control CIRB||Available to Open|
|AAML1031||COG||A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD||Pediatric CIRB||Available to Open|
|D9902||COG||A COG Soft Tissue Sarcoma Diagnosis; Biology and Banking Protocol||Pediatric CIRB||Available to Open|
|ADVL1712||COG||A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome||Pediatric CIRB||Available to Open|
|RTOG-0521||RTOG||A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT followed by Chemotherapy with Docetaxel and Prednisone for Localized; High-Risk Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1010||RTOG||A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1607||SWOG||A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|